|
Samaritan Pharmaceuticals,
Inc. (OTC BB:SPHC.OB), a developer of innovative drugs, is pleased
to announce it has received a price approval from the Greek
Ministry of Development for AMPHOCIL®.
This represents a major achievement in that Samaritan was
able to obtain a price increase reaching the level of 94%,
which is the second highest price increase granted by the
Ministry.
AMPHOCIL®
was in-licensed to Samaritan by Three
Rivers Pharmaceuticals LLC. Samaritan was granted
marketing authorization for AMPHOCIL®
in April of 2006 in Greece; however Samaritan needed to
apply for a price increase for it to be profitable. Samaritan
expects to launch AMPHOCIL®
in Greece next month.
Dr. Greeson,
CEO of Samaritan Pharmaceuticals stated, ``Dr. Christos
Dakas is to be credited for his tireless enthusiasm and
perseverance in getting this price approval from the Greek
Ministry of Development. We believe AMPHOCIL®
will play an important role in treating life-threatening
fungal infections and we are pleased to be a part of making
it available in Greece.''
Samaritan
is marketing AMPHOCIL®
for use in treating life-threatening opportunistic infections,
that often afflict immuno-compromised patients, such as people
with AIDS, transplant patients receiving immunosuppressant
therapy, and cancer patients receiving chemotherapy or radiation
treatment. Growth in these patient populations and the related
increase in opportunistic infections are linked to rapid growth
in the antifungal therapy market.
About
Samaritan Pharmaceuticals: ``We LIV....to Save Lives.''
Samaritan is a
small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics' for AIDS, Alzheimer's, Cancer and
Heart disease patients. Look at http://www.samaritanpharma.com.
Please register on Website so we can notify you of upcoming
conference calls, news and events.
Samaritan Pharmaceuticals
-- Samaritan Technology Videos: http://www.samaritanpharma.com/samaritan_mechanism_of_action_videos.asp
The company
disclaims any information that is created by an outside party
and endorses only information that is communicated by its
press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current
beliefs about the potential for its drug candidates, science
and technology. However, as with any biopharmaceutical under
development, there are significant risks and uncertainties
in the process of development and regulatory review. There
are no guarantees that products will prove to be commercially
successful. For additional information about the factors that
affect the company's business, please read the company's latest
Form 10-K/A filed November 2, 2006. The company undertakes
no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
Samaritan
In-Licensed AMPHOCIL® Awarded 94 Percent Price Increase
With Pricing Approval in Greece
